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BACKGROUND: Diabetes mellitus is a group of heterogeneous 
disorders of multiple etiologies characterized by chronic hyperglycemia 
resulting from defects in insulin secretion and/or insulin action. 
Diabetes mellitus has been reported to disturb normal hemostasis by 
various mechanisms. However, data on hemostasis of diabetic patients 
in the study area are lacking. This study was aimed at determining 
hemostatic profile and associated factors of hemostatic abnormality in 
diabetic patients. 
METHODS: A comparative cross-sectional study was conducted 
involving a total of 238 (119 diabetic and 119 apparently healthy) 
individuals who came to the chronic care clinic, Jimma University 
Specialized Hospital. Socio-demographic and clinical data were 
collected through a structured questionnaire. A blood sample of 10ml 
was collected in EDTA (4ml), citrate (3ml) and chemistry (3ml) tubes to 
do platelet count, coagulation tests, and glucose and lipid profile 
analysis, respectively. Descriptive statistics as well as the median (25th, 
75th) percentile and Mann Whitney U test were used during data 
analysis. 
RESULTS: The overall hemostatic abnormality in diabetes individuals 
was 58.8%. The median (25th, 75th percentile) prothrombin time for 
diabetic and non-diabetic subjects was (12.8, 15.6) vs. (12.8, 14.2), 
respectively, and the difference was not statistically significant 
(p>0.05). The median (25th, 75th percentile) activated partial 
thromboplastin time was significantly different between the two groups 
(p<0.0001); (24, 36.8) vs. (36, 39.6). The median (25th, 75th percentile) 
fibrinogen level was significantly different between the two groups 
(p<0.0001); (277, 462) vs. (243, 328). The median (25th, 75th 
percentile) platelet count was also significantly different between the 
two groups (p<0.0001); (146,248) vs. (190,319). All variables were not 
significantly associated with hemostatic abnormality in multivariate 
regression analysis. 
CONCLUSION: An overall hemostatic abnormality in diabetic patients 
was found to be high. The APTT and platelet count were lower in 
diabetic patients whilst the fibrinogen level was higher. Routine 
coagulation tests should be part of tests among diabetic patients. 
Advanced coagulation tests should also be considered to identify 
specific markers so as to pinpoint the particular problem. 
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Diabetes mellitus (DM) is a group of 
heterogeneous disorders of multiple etiologies 
characterized by chronic hyperglycemia resulting 
from defects in insulin secretion and/or insulin 
action (1). On the other hand, hemostasis is a 
normal body response which enables an organism 
to keep the blood in a fluid state, close off 
damaged blood vessels if vascular injury occurred, 
and remove blood clots after restoration of 
vascular integrity (2). There has been a body of 
evidence which suggests that diabetes mellitus can 
disturb normal hemostasis (3,4). Hyperglycemia 
affects multiple steps of coagulation such as 
thrombus formation and inhibition, fibrinolysis, 
platelet, and endothelial function (5). 
Increased platelet activity or enhanced 
activation and its mechanism in diabetes mellitus 
are evident in multiple studies. This is due to a 
combination of factors including the effects of 
insulin, hyperglycemia, hyperlipidemia, 
endothelial dysfunction, oxidative stress, and 
inflammatory state (6-8). High expression of GPIb 
(Glycoprotein Ib) and GPIIb/IIIa (Glycoprotein 
IIb/IIIa) for agonists and adhesive proteins on the 
platelet surface and increased fibrinogen binding 
was observed in diabetic patients (9). 
Factor VII (FVII) levels increases in 
metabolic syndrome subjects and Type 2 DM 
patients which is related to the dyslipidemia is 
present in both conditions (10). Factor VIII is also 
increased in women with Type 2 DM which may 
not be due to the presence of endothelial 
dysfunction and/or an inflammatory process (11). 
Patients with Type 2 diabetes have a high 
prevalence of hyperfibrinogenemia, and fibrinogen 
level is independently associated with hemoglobin 
A1C values according to a study in India (12). 
These hemostatic disturbances in diabetes favor the 
hypercoagulate wing of hemostasis which in turn 
results in atherosclerosis and thrombosis. A study 
has shown that patients with diabetes are at high 
risk for myocardial infarction and stroke, with 75% 
of deaths secondary to cardiovascular complications 
(13). 
Prothrombin time (PT), activated partial 
thromboplastin time (aPTT), platelet count, and 
fibrinogen level are global coagulation tests used 
to assess the coagulation system in a clinical 
setting. Patients with lower APTT are at increased 
risk for venous thromboembolism according to the 
Atherosclerosis Risk in Communities (ARIC), a 
study which investigated a-13-year risk of 
thromboembolism in relation to baseline APTT in 
13,880 individuals (14). 
Studies in other areas regarding coagulation 
profile in diabetic patients came up with a range of 
findings. Some studies showed that PT and APTT 
are significantly lower in diabetic than non-
diabetic individuals (15,16) while others showed 
that it is only APTT which is significantly lower in 
diabetic individuals as compared to the controls 
(17,18,19). 
There is scarcity of data on hemostasis in 
general population and DM patients in particular in 
Ethiopia. Therefore, the aim of this study was to 
determine hemostatic profile and associated risk 
factors of hemostatic abnormality in diabetic 
patients. 
 
MATERIAL AND METHODS 
 
Study setting: A comparative cross-sectional 
study was conducted from April 20 to May 10, 
2014 in the Chronic Care Clinic, Jimma University 
Specialized Hospital. A total of 238 (119 diabetic 
and 119 apparently healthy individuals) were 
included in the study by convenient sampling 
technique. A Fsting blood sugar of 126 mg/dl and 
110mg/dl was used as a cut-off value for diabetic 
and non-diabetic group, respectively. Diabetic 
individuals who were on anticoagulant therapy, 
pregnant women, individuals with a history of 
venous thromboembolism or known inherited 
coagulation disorders, and with recent surgical 
procedure were excluded.  Apparently healthy 
individuals who attended the laboratory for 
medical checkup and were negative for C-reactive 
protein test were included in the non-diabetic 
group.  
 
Data collection and laboratory testing: Socio-
demographic and clinical data were collected using 
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structured questionnaire and checklist. Ten ml of 
12 hours fasting venous blood was collected and 
transferred to EDTA tube (4ml), 3.2% citrated tube 
(3ml) and plain tube (3ml). A Serum prepared 
from plain tube was used to determine glucose 
level and lipid profile by using Chemistry analyzer 
(HeCoS, Italy). C-reactive protein was determined 
based on CRP latex particles agglutination test 
method (CRP-turbidimetry, linear chemicals, S.L.) 
to recruit healthy individuals. Platelet poor plasma 
was prepared from the sample in the citrated tube 
after centrifuging at 1500g for 15 minutes to 
analyze PT, APTT, and Fibrinogen level by a 
coagulation analyzer (Ares linear, Spain). EDTA 
tube sample was used to determine platelet count 
by making use of cell counter (HeCoS, Italy). The 
test was performed immediately after the 
collection of the sample. 
Statistical analysis: Descriptive statistics was 
employed to determine frequency and percentage. 
The median (25th, 75th percentile) was used to 
compare hemostatic profiles between diabetic and 
non-diabetic individuals. The significance of the 
differences of medians between diabetics and non-
diabetics were determined by using two-sample 
Wilcoxon rank-sum (Mann-Whitney) test. Factors 
associated with hemostatic profiles in diabetics 
and apparently healthy non-diabetic individuals 
were determined by binary logistic regression 
analysis controlling for confounding variables. 
Odds ratio, and its 95% confidence interval was 
reported.  P-value of less than 5% (p<0.05) was 
taken as statistically significant. 
Ethics: Ethical approval was obtained from the 
Ethical Review Committee of Jimma University 
Institute of Health. Written informed consent was 
obtained from each participant after a clear 
explanation of the purpose of the study, the 
procedure, benefits and possible discomfort and 
the right to voluntary participation. Confidentiality 
was mainstsined for any information obtained 




Demographic and clinical data: A total of 238 
individuals were involved in the study, 119 in each 
group.  Among the 119 diabetes patients, 
67(57.3%) were males while in non-diabetics, 
50(42.7%) were males. The majority of the 
diabetic patients were within the age group of 40-
65 (78.2%) years. The majority of DM participants 
had attended primary education 36(36.4%) 
(Table1). 
 
Table 1: Reference ranges used for hemostatic 
parameters in the study. 
 
Hemostatic parameters  Reference ranges 
PT 10-15 seconds 
APTT 25-43 seconds 
Fibrinogen Level 200-400mg/dl 
Platelet count 150-400 x 103/µl 
 
Female participants in both groups were not using 
oral contraceptive. Type 2 DM was 97(81.5%) of 
the diabetics, and the mean duration of diabetes 
was 8(+3.4) years. Out of the 119 diabetics, 
33(27.7 %) had complications such as neuropathy 
(4(3.4%)), retinopathy (18(15%)), chronic kidney 
disease (19(16%)), and chronic heart disease 
(5(4%)). Diabetic patients were categorized into 
two groups depending on the fasting blood sugar 
(FBS) values i.e.  70-130 mg/dl (good control) and 
>130mg/dl (poor control). The mean FBS level 
was (227.9+87.5) mg/dl, and the majority, 
104(87.4%), were in uncontrolled FBS level 
(Table 2). 
 
Table 2: Clinical Data of diabetic individuals at 
JUSH chronic care center, southwest Ethiopia, 
from April to June 2014. 
 
            Variables  No (%) 
Type of diabetes Type 1 22(18.5) 
 Type 2 97(81.5) 
Duration of 
diabetes 
<8 years 72(60.5) 
 >8 years  47(39.5) 
DM Complication   Yes  33 (27.7) 
   No 86(72.3) 
Control of FBS Good control 15(12.6) 
 Poor control 104(87.4) 
Hypertension   Yes  42(35.3) 
   No 77 (64.7) 
Body Mass Index    Normal 57 (47.8) 
   Abnormal(obese) 62  (52.0) 
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Hemostatic profile: The overall hemostatic 
abnormality in diabetes was 70(58.8%) while in 
non-diabetic individuals, it was 19(16%). The 
analysis has showed that the 25th median and the 
75th percentile of PT were not significantly 
different between diabetics and non-diabetics (p> 
0.05) whilst the 25th, median and 75th percentile 
of APTT, platelet count and fibrinogen level were 
significantly different between the two groups 
(p<0.0001). A significant difference was observed 
between the groups in the overall hemostatic 
abnormality (P<0.001) and fibrinogen accounts for 
the highest proportion (Table 3). 
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PT(second) 85(71.4) 34(28.6) 13.7 12.8              15.
6            
108(90.7) 11(9.3
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13.6 12.8 14.2 0.09 
APTT 
(seconds) 
86(72.3) 33(27.7) 31 24 36.
8 








84(70.6) 35(29.4) 199 146 248 116(97.4) 3(2.6) 238 190 319 <0.000
1 
Total  49(41.2) 70(58.) 
   
100(84.0) 19(16)    <0.000
1 
 
Associated factors: The main biochemical 
characteristics of diabetes patients and te control 
group are summarized in Table 4. In the 
multivariate logistic regression, there were no 
significant associations between plasma levels of 
total cholesterol (TC), triglycerides (TG), HDL-
cholesterol, and hemostatic abnormality. In the 
bivariate logistic regression analysis, age, 
residence, duration of DM, uncontrolled FBS 
level, hypertension, obesity, and high LDL (low 
density lipid) were significantly associated with 
hemostatic abnormality in diabetic individuals. 
Following adjustment in a multivariate regression 
model, none of the variables were significantly 
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Hemostasis Abnormality COR (95% C. I) P-Value AOR (95% C. I) P-value 
Normal Abnormal 
Age 
18-39 19(52.8) 17(47.2) --    
40-64 24(35.3) 44(64.7) 4.368(2.44 -7.82) 0.000 2.143(.613.491) 0.232 
>_65 6(40) 9(60) 5.08(1.67 -15.38) 0.000 1.426(.26-7.81) 0.682 
Sex 
M 29(43.3) 38(56.7) 1.175(0.69 – 1.98) 0.547  0.547 
F 20(38.5) 32(61.5)     
Location 
Urban 22(40) 33(60) -    
Rural 27(42.2) 37(57.8) 1.707(1.00 – 2.90) 0.048 .994(.38-2.54) 0.990 
Education 
Illiterate 10(37) 17 (63) 1.417(0.29 – 6.81) 0.664  0.664 
Read& write 9(34.6) 17 (65.4) 0.595(0.13 – 2.62) 0.492  0.492 
Pre. school 16(44.4) 20(55.6) 0.41(0.09 – 1.77) 0.234  0.234 
Sec. school 10(45.5) 12(54.5)  0.65( 0.582  0.582 
Above 
secondary 
4(50) 4(50) - -   
Type of DM 
Type I 13(59.1) 9(40.9)     
Type II 36(37.1) 61(62.9) 2.448(0.95 – 6.29) 0.063 0.55(.110-2.76) 0.469 
FBS level 
controlled 15(100) 0(0) -    
uncontrolled 34(32.7) 70(67.3) 12.74(6.5 – 24.85) 0.000 3.787E9(0.00 0.998 
Duration DM 
<_8 years 35(48.6) 37(51.4) --    
>8years 14(29.8) 33(70.2) 2.230(1.02– 4.85) 0.043 1.72(0.63-4.67) 0.288 
DM complication 
Yes 11(33) 22 (66.7) 1.583 (0.68– 3.66) 0.283   
No 38(44) 48 (56) --    
Blood Pressure 
High  12 (29) 30 (71) 2.31(1.03 – 5.17) 0.041 2.18(.79-6.02) 0.131 
Normal 37 (48) 40  (52) --    
Body Mass Index 
Normal 27(47) 30(53)     
Abnormal 22(35) 40(65) 2.610(1.49 – 4.55) 0.001 1.58(0.58-4.33) 0.366 
Total Cholesterol mg/dl 
<_200 l 36(48) 39(52)     
>200  12(28) 31(72) 2.201(0.99- 4.85) 0.050 1.482(.53-4.16) 0.456 
Triglycerides mg/dl 
<_150  8(62) 5(38)     
>150  41(39) 65(61) 2.537(0.77 8.28) 0.123 1.764(.38-8.02) 0.463 
HDL mg/dl 
>_40  49(42) 68(58)     
<40  0(0) 2(100) 5.163(0.53-50.4) 0.163 8.433E8(.000- 0.999 
LDL mg/dl 
               
   
                 Ethiop J Health Sci.                           Vol. 29, No. 2                     March 2019 
 
 




<_100  38( 48) 41(52)     




The overall hemostatic abnormality in diabetics 
was higher than in the non-diabetics. The median 
(25th, 75th percentile) APTT, fibrinogen level 
and platelet count were significantly different 
between the two groups while PT has showed no 
significant difference between the groups. 
PT and APTT tests are standard screening 
tests for function of the coagulation system, and 
their utility in monitoring therapeutic 
anticoagulation is widely accepted. A multicenter 
cohort study showed that baseline APTT below 
the median was associated with increased risk of 
future venous thromboembolism after adjustment 
for demographic factors and relevant hemostatic 
factors (14). In this study, the APTT in the 
diabetic patients showed a shortened value as 
compared to the non-diabetics, and the median 
(25th, 75th percentile) was significantly different 
between the two groups. This finding is in 
agreement with the study done in Tribhuvan 
University Teaching Hospital (TUTH) which 
showed that there was a decrease in the value of 
APTT in diabetics than nin on-diabetics; the 
difference was statistically significant (17). A 
similar finding was observed in the study done in 
China. Statistically significant difference was 
observed in the APTT when the high-risk diabetic 
group was compared with the normal group (18). 
The same is true for the study in Turkey which 
revealed that there was significantly shortened 
APTT in both diabetic group and impaired fasting 
glucose (IFG) group as compared to the 
euglycemic group (19). Mean prothrombin time 
(PT) and activated partial thromboplastin time 
(APTT) levels were significantly (P<0.001) lower 
in patients with diabetes mellitus than those of 
control groups according to the study done in 
Dhaka Medical college, Bangladesh (20). 
Fibrinogen level is useful as part of the 
investigation of bleeding tendency or an 
unexplained prolongation of the APTT or PT. 
Elevated levels may correlate with increased risk 
of thrombosis in epidemiological studies although 
the significance in individual patients is unclear 
(21). In this study, PT was not significantly 
different between the two groups while fibrinogen 
level showed a significant difference, higher in 
the diabetic group. This is in accordance with the 
study done in India which showed that there was 
a rise in plasma fibrinogen levels in diabetics as 
compared to controls (22). Another study done in 
India showed the same result which is an 
increased serum fibrinogen level in all diabetic 
patients as compared to non-diabetic controls 
(23). It was also seen that in the diabetic subset, 
the plasma fibrinogen levels were significantly 
higher than the non-diabetic subset in another 
study (12). 
Platelets of diabetic individuals have 
abnormal tendency of increased activity and 
aggregation which lead to thrombus formation of 
microcapillary embolization and local vascular 
lesions (24). The median platelet count showed 
statistically significant difference between 
diabetics and non-diabetics. This is in agreement 
with the study done by Hekismoy et al. which 
showed that the mean platelet counts were 
significantly lower in diabetics as compared to 
age- and sex-matched non-diabetic healthy 
controls (25). 
In conclusion, overall hemostatic 
abnormality in diabetic patients was found to be 
high. The PT value revealed no statistical 
difference between the two groups. The APTT 
and platelet count were lower in diabetic patients 
whilst the fibrinogen level was higher. This study 
recommends that routine coagulation tests should 
be part of tests in diabetic patients during follow-
up along with clinical diagnosis. Advanced 
coagulation tests should also be considered by 
future studies to identify specific markers so as to 
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